Cambridge-based Tokai Pharmaceuticals Inc. said today it is treating the first patient in the company's ARMOR2 trial, a clinical study of its lead drug candidate galeterone, which is designed to treat patients with castration-resistant prostate cancer.
This is the second study in Tokai's Androgen Receptor Modulation Optimized for Response clinical development program for the evaluation of galeterone, a proprietary small molecule, oral drug that disrupts the growth and survival of prostate cancer cells.
Results from the ARMOR1 trial showed that galeterone had clinical activity and was well-tolerated in patients with CRPC, the company said.
Up to 196 patients, including those who are "treatment-naive" and those who have progressed while taking the androgen-directed hormonal therapy, Zytiga, will be enrolled in the ARMOR2 trial, Tokai said.
The company added galeterone received fast-track designation from the U.S. Food and Drug Administration this year.
Anda sedang membaca artikel tentang
Tokai Pharma announces start of prostate cancer drug trial
Dengan url
http://terdiamtersipu.blogspot.com/2012/12/tokai-pharma-announces-start-of.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Tokai Pharma announces start of prostate cancer drug trial
namun jangan lupa untuk meletakkan link
Tokai Pharma announces start of prostate cancer drug trial
sebagai sumbernya
0 komentar:
Posting Komentar